Sanjivani Paranteral reported a strong performance for the quarter ended September 30, 2026, with consolidated net profit jumping to Rs 4.15 crore from Rs 1.64 crore in the year-ago period. Consolidated revenue from operations grew significantly to Rs 25.33 crore, reflecting a positive operational trajectory for the pharma player.
Sanjivani Paranteral Reports Strong Growth in Q2 FY27
Consolidated Revenue: Rs 25.33 Crore | Net Profit: Rs 4.15 Crore
Reader Takeaway: Revenue and profit both show triple-digit growth, though investors should monitor margins as operations scale further.
What just happened
Sanjivani Paranteral Ltd released its unaudited financial results for the quarter ended September 30, 2026. The company saw significant year-over-year growth across all major financial metrics. Consolidated revenue from operations reached Rs 25.33 crore, compared to Rs 15.50 crore in the same quarter last year. Profitability improved even more sharply, with net profit rising to Rs 4.15 crore from Rs 1.64 crore.
Why this matters
The results indicate a substantial expansion in the company's business scale. Standalone operations also mirrored this trend, with revenue rising to Rs 19.30 crore and standalone net profit increasing to Rs 2.21 crore. The clean limited review report from statutory auditors R. B. Gohil & Co. confirms that the financial statements comply with standard accounting practices, providing a baseline of stability for the latest numbers.
What to track next
Investors should focus on the sustainability of this revenue growth in upcoming quarters. Given the significant jump in net profit, it will be essential to observe whether the company can maintain these margins while managing higher operational volumes.